Vetter’s V-OVS® next Earns Prestigious Red Dot Design Concept Award

Novel syringe closure system honored for its innovative design and enhanced user experience

Vetter%E2%80%99s V
Vetter%E2%80%99s V
Vetter logo standard dark blue rgb
Vetter logo standard dark blue rgb

  • Award recognizes innovative design concept
  • New syringe closure system builds on more than two decades of market success

RAVENSBURG, Germany–(BUSINESS WIRE)–Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has received a Red Dot Award in the category “Design Concept” for its next-generation syringe closure system, V-OVS® next. The internationally recognized award honors forward-looking product concepts distinguished by innovation, functionality, and design excellence. The recognition highlights Vetter’s continued commitment to developing an advanced closure system that improves the user experience while supporting the evolving needs of pharma and biotech companies.

Developed in response to growing market complexity, particularly in biologics and user-oriented drug products, V-OVS® next represents the latest evolution of Vetter’s syringe closure technology. The system incorporates multiple design enhancements intended to improve safety, usability, and compatibility across a range of syringe formats, helping to establish a new standard for Luer Lock syringe closure systems.

“We are honored that V-OVS® next has been recognized with a Red Dot Award,” said Dr. Claus Feussner, Senior Vice President Development Service at Vetter. “This achievement reflects our commitment to combining technical innovation with meaningful user insights. Throughout development, we focused on creating a closure system that enhances functionality and patient safety, while delivering a more intuitive handling experience. Awards like this confirm that innovative pharmaceutical packaging must address both technical requirements and human factors to deliver meaningful value.”

One of the system’s key features is a robust locking mechanism designed to provide a secure connection between the syringe and the closure part, helping to reduce the risk of unintended rotation. V-OVS® next also incorporates a tamper-evident seal that irreversibly breaks upon first opening, offering an immediate visual indication of product status while supporting safety, product integrity, and user confidence.

In addition to its technical advancements, the closure system was specifically engineered with user-centric design principles. Ergonomic gripping elements help users intuitively identify handling points, while integrated visual opening indicators contribute to a straightforward opening process. The overall design combines functionality with a premium appearance, enabling pharma and biotech companies to further differentiate their therapies in an increasingly competitive marketplace.

Find the Vetter press kit and more background information here.

About Vetter

Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the independent pharmaceutical service provider is also present in the Asia-Pacific markets of Japan, China, South Korea and Singapore with sales locations. Around the world renowned pharma and biotech companies benefit from decades of experience, high quality, modern technologies, reliability, and commitment of its 7,400 employees. In close collaboration with its customers, the Vetter team helps enable the supply to patients all over the world with medicines, many of which are vital. The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative approaches, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. Vetter takes responsibility for sustainable practices and operates as a socially and ethically responsible corporate citizen. The CDMO is a member of the UN Global Compact and Science Based Target initiative (SBTi) and received platinum status in the renowned EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership Award and the recognition of Best Managed Company emphasize Vetter’s commitment to sustainable business. Founded in Ravensburg in 1950, the company remains family-owned to this day. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.

Contacts

Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg
Germany
Phone: +49 (0)751-3700-3729
Email: [email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.